News & Updates
Filter by Specialty:

Lebrikizumab plus TCS improves outcomes in moderate-to-severe AD
23 Mar 2024
byStephen Padilla
Treatment with lebrikizumab in combination with topical corticosteroids (TCS), compared with TCS alone, results in early and sustained improvements in patient-reported outcomes (PROs) among individuals with moderate-to-severe atopic dermatitis (AD), as shown in a Japan study.
Lebrikizumab plus TCS improves outcomes in moderate-to-severe AD
23 Mar 2024
Intramuscular injection preferable to IV infusion of ibalizumab for PWH
22 Mar 2024
byStephen Padilla
Ibalizumab delivered via intramuscular (IM) injection is not only safe and well-tolerated but also succeeds in viral suppression among heavily treatment experienced (HTE) people living with HIV (PWH), making IM the preferred method of administration among participants of the TMB-302 study.